Twist Bioscience (NASDAQ:TWST) CEO Sells $922,908.14 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 5,203 shares of the business’s stock in a transaction on Thursday, September 24th. The shares were sold at an average price of $177.38, for a total transaction of $922,908.14. Following the completion of the sale, the chief executive officer directly owned 613,699 shares in the company, valued at $108,857,928.62. This trade represents a 0.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Twist Bioscience Price Performance

NASDAQ:TWST opened at $182.83 on Monday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. The company has a 50-day moving average of $126.89 and a 200-day moving average of $87.41. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $186.20. The company has a market capitalization of $11.47 billion, a price-to-earnings ratio of -82.36 and a beta of 2.22.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The business had revenue of $118.38 million during the quarter, compared to the consensus estimate of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The business’s revenue was up 23.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.33 EPS. As a group, equities research analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on TWST shares. Evercore lowered Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price target on the stock. in a research note on Monday, July 6th. TD Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 3rd. Leerink Partners lifted their price target on Twist Bioscience from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Thursday, September 17th. BWS Financial reiterated a “sell” rating and set a $45.00 price target on shares of Twist Bioscience in a research report on Friday, September 18th. Finally, Robert W. Baird increased their price objective on shares of Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Twist Bioscience has a consensus rating of “Moderate Buy” and a consensus target price of $103.00.

Hedge Funds Weigh In On Twist Bioscience

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC lifted its stake in Twist Bioscience by 24.4% in the second quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock valued at $97,000 after buying an additional 185 shares during the period. Allworth Financial LP raised its position in shares of Twist Bioscience by 54.9% in the 2nd quarter. Allworth Financial LP now owns 601 shares of the company’s stock valued at $62,000 after acquiring an additional 213 shares during the period. PNC Financial Services Group Inc. raised its position in shares of Twist Bioscience by 89.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock valued at $46,000 after acquiring an additional 453 shares during the period. Trifecta Capital Advisors LLC bought a new position in Twist Bioscience during the 2nd quarter worth approximately $63,000. Finally, Intech Investment Management LLC boosted its stake in Twist Bioscience by 2.6% during the 4th quarter. Intech Investment Management LLC now owns 25,477 shares of the company’s stock worth $808,000 after acquiring an additional 643 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.